Form 4: GoodRx Director Ronald Bruehlman Granted Over 57,000 Deferred Stock Units

GoodRx Holdings, Inc. Director Ronald E. Bruehlman was granted 57,050 deferred stock units, convertible into Class A common stock, as part of his compensation, vesting on the earlier of June 3, 2026, or the 2026 Annual Meeting.

Summary

• Ronald E. Bruehlman, a Director of GoodRx Holdings, Inc. (GDRX), acquired 57,050 Class A Common Stock deferred stock units on June 3, 2025.
• These deferred stock units were acquired at a price of $0, indicating they are part of an equity compensation grant.
• Following this transaction, Mr. Bruehlman beneficially owns a total of 89,334 Class A Common Stock units.
• Each deferred stock unit represents a contingent right to receive one share of Class A common stock.
• The units are set to vest in full on the earlier of June 3, 2026 (one-year anniversary of the grant date) or the date of the 2026 Annual Meeting of Stockholders, subject to continued service.
• Settlement of the deferred stock units into Class A common stock will occur on the earliest of December 31, 2030, separation from service, a change in control, death, or disability, as defined under the company's Deferred Compensation Plan for Directors.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is a positive signal of alignment between management and shareholders, though not indicative of extraordinary performance or strategic shifts.

Positives

• The grant of deferred stock units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for attracting and retaining experienced board members in publicly traded companies.

Future Outlook

The deferred stock units granted to the director are subject to future vesting conditions, primarily continued service, and will settle into Class A common stock on specific future dates or events, providing a long-term incentive for the director.

Management Comments

• "Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock."
• "The deferred stock units vest in full on the earlier of (i) the one-year anniversary of June 3, 2025 and (ii) the date of the 2026 Annual Meeting of Stockholders, subject to continued service through the applicable vesting date."
• "The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2030; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors)."

Industry Context

GoodRx operates in the digital healthcare and prescription savings industry. The grant of deferred stock units to a director is a common form of non-cash compensation in publicly traded companies across various industries, including healthcare technology, to align the interests of board members with long-term shareholder value.

Comparison to Industry Standards

• The grant of deferred stock units as equity compensation for directors is a standard practice in publicly traded companies, aligning with common corporate governance and compensation benchmarks.
• The specific number of units granted would typically be determined by the company's compensation committee based on factors such as director responsibilities, market rates for similar roles, and the company's overall compensation philosophy, which is consistent with industry norms.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of deferred stock units by Ronald E. Bruehlman, a Director of GoodRx Holdings, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of equity compensation to a director aligns their interests with shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees from this specific filing.

Next Steps

• Vesting of the 57,050 deferred stock units on the earlier of June 3, 2026, or the 2026 Annual Meeting of Stockholders.
• Eventual settlement of the vested deferred stock units into Class A common stock based on the specified settlement events.

Key Dates

Recommendation

Keywords

GoodRx, GDRX, SEC Form 4, Insider Transaction, Deferred Stock Units, Equity Compensation, Director Compensation, Ronald Bruehlman